Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Enrolling by invitation 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Rectal Neoplasms 13Squamous Cell Carcinoma of Head and Neck 11Esophageal Neoplasms 11Uterine Cervical Neoplasms 8Carcinoma, Non-Small-Cell Lung 8Head and Neck Neoplasms 7Pancreatic Neoplasms 6Oropharyngeal Neoplasms 6Nasopharyngeal Carcinoma 6Carcinoma, Squamous Cell 5Esophageal Squamous Cell Carcinoma 3Carcinoma 3Thymoma 2Stomach Neoplasms 2Neoplasms by Site 2Neoplasms 2NSCLC 2Lymphoma 2Hypopharyngeal Neoplasms 2Glioblastoma 2Colorectal Neoplasms 2Adenocarcinoma Of Esophagus 2Urinary Bladder Neoplasms 1Thrombocytopenia 1Small Cell Lung Carcinoma 1Sinonasal undifferentiated carcinoma 1Sinonasal Squamous Cell Carcinoma 1SCLC, Extensive Stage 1Resectable Esophageal Cancer 1Rectal Malignant Neoplasms 1

Interventions

Gemcitabine 2tremelimumab 1irinotecan sucrosofate 1durvalumab 1Taxes 1Oxaliplatin 1Medical Marijuana 1Leucovorin 1Fluorouracil 1Chemoradiotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Pancreatic Cancer Non-resectable × Chemoradiotherapy × Clear all
NCT07386704 2026-02-04

Nimotuzumab Combined With Chemoradiotherapy in the Treatment of Unresectable Locally Advanced or Oligometastatic Pancreatic Cancer

Peking University First Hospital

Phase 2 Enrolling by invitation
30 enrolled
Gastrointestinal

Pancreatic Cancer Non-resectable

Data powered by HemOnc (CC BY 4.0) Colophon âš¡